Yes, Pulmicort is often combined with a short-acting bronchodilator (e.g., salbutamol) for relief of acute symptoms. The two devices serve different purposes-Pulmicort for maintenance and the bronchodilator for rescue-so using both as prescribed is safe.
Rinse your mouth with water and spit after each inhalation. If thrush appears, contact a healthcare professional; an antifungal mouthwash or lozenge may be prescribed, and the inhaled dose may be adjusted.
Cigarette smoke can increase airway inflammation and reduce the local effectiveness of inhaled corticosteroids. Quitting smoking improves overall asthma control and enhances the benefit of Pulmicort.
The inhaler can be kept for recycling or disposal, but the mouthpiece should be removed and cleaned. Do not attempt to refill the device; use a new, prescription-filled inhaler for subsequent treatment.
A correct technique includes a slow, deep inhalation, holding the breath for 5-10 seconds, and rinsing the mouth afterward. Healthcare providers can demonstrate the steps and may use a spacer device to confirm proper delivery.
Inhaled budesonide does not impair the immune response to most vaccines, including COVID-19. However, maintain routine vaccination schedules and discuss any concerns with your clinician.
Yes, but carry the prescription label and a copy of the doctor’s note. Some countries may require documentation for inhaled corticosteroids; check airline and destination regulations before departure.
Both deliver the same medication; the 200 µg inhaler provides a higher dose per actuation, allowing fewer pushes per dose. Choice depends on the prescriber’s assessment of disease severity and required total daily dose.
A spacer is optional but can improve drug deposition in the lungs, especially for children or patients who have difficulty coordinating inhalation. If used, follow the spacer’s specific cleaning instructions.
Patients may feel a reduction in symptoms within a few days, but optimal control usually develops after 2-4 weeks of regular twice-daily use. Consistency is key; missed doses can delay therapeutic benefit.
Pulmicort is a brand-name inhaler that contains budesonide as its active component. Budesonide belongs to the inhaled corticosteroid (ICS) class and is used to manage chronic airway inflammation associated with asthma and other breathing disorders. In the United Kingdom, Pulmicort is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). The inhaler is available in two fixed strengths: 100 µg and 200 µg per actuation.
Budesonide is a synthetic glucocorticoid that exerts anti-inflammatory effects on the respiratory tract. After inhalation, the drug is deposited directly onto the bronchial mucosa where it:
Because the medication acts locally in the airways, systemic exposure is low. The onset of anti-inflammatory action typically begins within a few hours, but full clinical benefit may require several weeks of regular use. The medication’s duration of effect lasts for about 12 hours, supporting twice-daily dosing for most patients.
Pulmicort is approved by the MHRA for the following indications:
In clinical practice, inhaled budesonide is sometimes employed off-label for chronic obstructive pulmonary disease (COPD) when other therapies are insufficient, but this use requires careful physician oversight.
Evidence-Based Off-Label Uses
Off-label use requires medical supervision and an individualized risk assessment.
Investigational research is exploring budesonide’s role in early-stage interstitial lung disease and in preventing post-viral airway inflammation, but these applications remain experimental.
If any of these conditions apply, discuss alternatives with a prescriber before initiating Pulmicort.
Safety Note: Patients should inform their healthcare provider of all prescription medicines, over-the-counter products, herbal supplements, and vaccines before starting Pulmicort.
Standard dosing (based on prescribed strength):
100 µg inhaler - typically 2 actuations (200 µg total) twice daily.
200 µg inhaler - usually 1 actuation (200 µg) twice daily.
Administration technique
Shake the inhaler gently before each use.
Exhale fully, place the mouthpiece between the teeth, and seal lips around it.
Press down firmly while breathing in slowly and deeply.
Hold breath for 5-10 seconds, then exhale slowly.
Rinse mouth with water and spit out to reduce the risk of thrush.
Special populations
Renal or hepatic impairment: No dosage adjustment is required for inhaled budesonide; however, clinicians may monitor for systemic effects.
Elderly: Same dosing as adults; ensure proper inhaler coordination.
Missed dose - Take the missed inhalation as soon as remembered unless the next scheduled dose is within a short interval (less than 4 hours); in that case, skip the missed dose and continue the regular schedule. Do not double the dose.
Overdose - Signs may include severe cough, wheezing, respiratory distress, or systemic corticosteroid effects (e.g., facial swelling). Seek emergency medical care; treatment is supportive, and corticosteroid antagonist therapy is not required.
Discontinuation - Abrupt cessation may lead to loss of asthma control. If a step-down is planned, taper the dose gradually under medical supervision to minimize rebound airway inflammation.
Routine laboratory tests are not required for inhaled budesonide unless a systemic corticosteroid effect is suspected.
This article provides educational information about Pulmicort and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
